Clinical Trials

Orbsen gets European approval to start diabetic kidney disease trial for Obrcel-M

Orbsen Therapeutics’ stromal cell immunotherapy, OBRCEL-M has been approved to begin testing in a randomised, double blind, and placebo-controlled clinical trial in Europe to treat diabetic kidney disease.

Merck, Generex to assess Keytruda in combination with AE37

Generex Biotechnology's subsidiary, Antigen Express has signed a clinical trial collaboration agreement with Merck, via a wholly-owned subsidiary, to assess Antigen’s AE37 cancer vaccine in combination with Merck’s anti-PD-1 (programmed death receptor-1) therapy, KEYTRUDA (pembrolizumab), in patients with metastatic triple-negative breast cancer.

AstraZeneca’s lung cancer immunotherapy trial fails to meet primary endpoint

AstraZeneca’s Imfinzi (durvalumab) in combination with tremelimumab failed to improve progression-free survival (PFS) significantly in a phase 3 trial in previously untreated patients having advanced lung cancer.

Alzheimer’s drug reduces hallmark inflammation related to metabolic syndrome by 25%

An existing Alzheimer’s medication has been found to cut inflammation and insulin resistance in patients with metabolic syndrome, as per new clinical trial results put up by scientists at Northwell Health’s The Feinstein Institute for Medical Research.

Incyte launches phase 3 trial of Itacitinib for acute graft-versus-host disease

Incyte reported that the first patient has been treated in a phase 3 trial dubbed GRAVITAS-301 for the first-line treatment of patients with acute graft-versus-host disease (GVHD).

Tiziana launches phase IIa trial of milciclib in HCC patients

Tiziana Life Sciences has started enrolling of patients in its phase IIa clinical trial with cyclin-dependent kinases (CDKs) inhibitor milciclib in patients with refractory hepatocellular carcinoma (HCC).

Vertex reports positive data from cystic fibrosis trials

Vertex Pharmaceuticals has reported positive data from Phase 1 and Phase 2 trials of three different triple combination regimens in cystic fibrosis (CF) patients who have one F508del mutation and one minimal function mutation (F508del/Min).

PureTech Health presents inflammation drug research data at Boston Conference

PureTech Health has presented data for product candidate ALV-107 showing durable pain control throughout a 24-hour study period, lasting at least 12 times longer than lidocaine at a comparable dose (ALV-107 16 mg/kg, conventional lidocaine 16 mg/kg), in a validated preclinical model for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS).

Elite reports topline results from bioequivalence fed study for SequestOx

Elite Pharmaceuticals has reported topline results from a pivotal bioequivalence fed study for SequestOx.